Psyence Biomedical Ltd. (PBM)
(Delayed Data from NSDQ)
$4.95 USD
+0.41 (9.03%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $4.94 -0.01 (-0.20%) 6:12 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PBM 4.95 +0.41(9.03%)
Will PBM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PBM based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for PBM
12 Health Care Stocks Moving In Monday's Intraday Session
Dow Jumps 1%; Tyson Foods Earnings Beat Views
PBM Advances in Psilocybin Study and Strengthens Financial Position
Corporate Update, August 2025 | PBM Stock News
Psyence Biomedical issues letter to shareholders